CME vs STRO · P/E 22, rev $6.52B vs rev $62.0M
CME Group Inc (CME) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
CME Group Inc (CME) is a financial data & stock exchanges company listed on NASDAQ.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported CME revenue for 2025-12-31 was $6.52B. Net income was $4.07B. Revenue was up 6.4% from 2024-12-31 to 2025-12-31. CME currently screens at market cap $91.25B and trailing P/E 21.9.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
CME currently screens at market cap $91.25B and trailing P/E 21.9. STRO currently screens at market cap $470.8M.
Not investment advice. Open the CME and STRO stock pages for the full models.
Not investment advice.